Work

TEMPORARY REMOVAL: Understanding self-reported treatment behaviors among people using glucagon-like peptide-1 receptor agonists for weight loss: A United States survey observational study

Year: 2026

Type: article

Abstract: Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight loss (WL) in the US. Research shows many people using GLP-1 RAs for WL personalize their dosing; however, the factors driving these decisions have not been well studied. This study explored the dosing behaviors of people using GLP-1 RAs for WL in the US, and their drivers. Methods This was an observational quantitative survey study. The survey was completed by 1,508 adults who had been using GLP-1 RAs primarily for WL for ≥3 months (currently or in the last 12 months). Participants were classified into dosing behavior groups through self-identification, verified by follow-up behavioral questions. Dosing behavior groups included dosing as prescribed, maximizing (increasing dosage faster than prescribed), minimizing (using less medication/increasing dosage more slowly than prescribed), or tinkering (increasing/decreasing flexibly). Results Participants were aged 25–65 years, 51% women, and from diverse socioeconomic backgrounds; most (62%) had a body mass index of 30–40 kg/m 2 . While 46% of participants used GLP-1 RA doses as prescribed, 12% reported maximizing, 19% minimizing, and 23% tinkering. Health literacy and perceived healthcare provider support in GLP-1 RA WL treatment, through knowledge-building or decision-making, were associated with a reduced likelihood of dosing adjustment. Health beliefs, including concerns about GLP-1 RA dependency, perceptions about GLP-1 RA use (e.g., “GLP-1 RAs should be taken for life”), and lack of partner support, were key drivers of dosing-adjustment behaviors. Conclusions Most participants reported personalizing their GLP-1 RA WL treatment dosing. These behaviors are shaped primarily by sociocultural factors and personal motivations and considerations. This study highlights the need for evidence-based, healthcare professional-facilitated individualized treatment plans to ensure dosing is aligned to the priorities of people using GLP-1 RAs for WL, and offers actionable targets for person-centered education and support for the use of GLP-1 RAs for WL.

Source: Obesity Pillars

DOI: 10.1016/j.obpill.2026.100328